Sublocade Solution
Product Images NDC 12496-0300

16 FDA label images from Indivior Inc. · Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 16 technical images submitted to the FDA as part of the official labeling for Sublocade (NDC 12496-0300). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Indivior Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Figure 1 (Sub0a 0053 01)

Figure 1 (Sub0a 0053 01)
Illustration showing a syringe with an attached safety needle device, depicting its design and components used for subcutaneous injection.*
FDA Label Image

Figure 2 (Sub0a 0053 02)

Figure 2 (Sub0a 0053 02)
An instructional illustration showing a close-up view of a syringe with a needle attached. The focus is on the syringe's barrel containing solution, highlighting the subcutaneous injection method relevant to the SUBLOCADE buprenorphine medication.*
FDA Label Image

Figure 3 (Sub0a 0053 03)

Figure 3 (Sub0a 0053 03)
An instructional diagram showing the process of assembling a syringe with a vial. The image depicts a syringe being held above a vial with a downward arrow indicating the syringe is to be inserted into the vial. This likely relates to preparing a subcutaneous solution dose of SUBLOCADE (buprenorphine) for administration.*
FDA Label Image

Figure 4 (Sub0a 0053 04)

Figure 4 (Sub0a 0053 04)
An anatomical illustration showing front and back views of a human torso and upper legs where a subcutaneous injection site is indicated for SUBLOCADE. The front view highlights the abdomen area as an injection site, while the back view highlights the upper buttock region, indicating appropriate locations for subcutaneous administration of this buprenorphine solution.*
FDA Label Image

Figure 5 (Sub0a 0053 05)

Figure 5 (Sub0a 0053 05)
An illustration showing a syringe being inserted into the top of a vial, depicting the process of drawing medication from the vial. The image is a black and white line drawing, suggesting an instructional or procedural diagram for medication preparation or administration.*
FDA Label Image

Figure 6 (Sub0a 0053 06)

Figure 6 (Sub0a 0053 06)
An instructional line drawing showing a hand inserting a syringe needle into the skin, representing subcutaneous injection technique.*
FDA Label Image

Figure 7 (Sub0a 0053 07)

Figure 7 (Sub0a 0053 07)
An instructional illustration showing a syringe being held at a 45-degree angle for subcutaneous injection into a patient's arm. The image demonstrates proper technique consistent with subcutaneous administration of a solution, such as buprenorphine subcutaneous injection.*
FDA Label Image

Figure 8 (Sub0a 0053 08)

Figure 8 (Sub0a 0053 08)
An instructional illustration depicting an injection being administered subcutaneously into an arm, showing a hand holding a syringe approaching the skin to deliver the dose. This image supports the use of SUBLOCADE (buprenorphine) solution for subcutaneous injection.*
FDA Label Image

Figure 9 (Sub0a 0053 09)

Figure 9 (Sub0a 0053 09)
An instructional illustration showing a hand holding a syringe poised for injection. The image depicts the motion of the hand pressing down on the plunger to administer the dose, suggesting use of a subcutaneous injection technique.*
FDA Label Image

Structural Formula (Sub0a 0053 10)

Structural Formula (Sub0a 0053 10)
Chemical structure diagram of buprenorphine, the active ingredient in SUBLOCADE. The structure shows multiple fused rings including a phenolic hydroxyl group, an ether linkage, and a tertiary amine, characteristic of this opioid partial agonist.*
FDA Label Image

Figure 10 (Sub0a 0053 11)

Figure 10 (Sub0a 0053 11)
A scatter plot graph showing placebo-corrected VAS drug-liking scores (mm) on the vertical axis against buprenorphine plasma concentration (ng/mL) on the horizontal axis. Data points are marked for baseline (no buprenorphine) and weeks 1-12 after SUBLOCADE injection, comparing drug-liking over plasma concentration levels.*
FDA Label Image

Figure 11 (Sub0a 0053 12)

Figure 11 (Sub0a 0053 12)
Bar chart presenting the distribution of fentanyl doses across three study arms (A, B, and C) with varying buprenorphine (BUP) concentrations, including placebo (PBO), low BUP, mid BUP, and high BUP. The graph shows proportions for four fentanyl dose categories as percentages, with sample sizes indicated for each arm.*
FDA Label Image

Figure 12 (Sub0a 0053 13)

Figure 12 (Sub0a 0053 13)
A two-part chart showing placebo-corrected visual analog scale (VAS) drug liking scores over a 12-week period for SUBLOCADE 300 mg administered subcutaneously. The upper chart depicts median differences with 95% confidence intervals for 6 mg and 18 mg hydromorphone. The lower chart shows individual VAS drug liking scores for the 6 mg and 18 mg hydromorphone doses during the study timeline. Time points are labeled by week, with annotations for SUBLOCADE dosing and sublingual film administration.*
FDA Label Image

Figure 13 (Sub0a 0053 14)

Figure 13 (Sub0a 0053 14)
A Kaplan-Meier survival curve chart showing the percentage of subjects with opioid-free weeks over time for SUBLOCADE 300 mg/300 mg plus IDC, SUBLOCADE 300 mg/100 mg plus IDC, and placebo plus IDC groups. The y-axis represents the percentage of subjects, and the x-axis represents the percentage of opioid-free weeks, comparing the effectiveness of different SUBLOCADE dosing regimens versus placebo.*
FDA Label Image

Principal Display Panel (Sublocade 100 mg Carton Label)

Principal Display Panel (Sublocade 100 mg Carton Label)
Packaging label for SubLocade 100 mg solution for injection, a buprenorphine extended-release product for subcutaneous use only. The label states it is a single-dose sterile syringe package labeled for Rx only, containing one prefilled syringe with 100 mg/0.5 mL buprenorphine in the ATRIGEL Delivery System. The labeler is Indivior Inc. Important warnings regarding serious harm or death if injected intravenously are prominently displayed.*
FDA Label Image

Principal Display Panel (Sublocade 300 mg Carton Label)

Principal Display Panel (Sublocade 300 mg Carton Label)
Packaging label for SubLocade 300 mg solution for injection, containing buprenorphine extended-release for subcutaneous use only. The label specifies a single sterile prefilled syringe of 300 mg/1.5 mL strength. Manufactured and labeled by Indivior Inc. Instructions emphasize administration by healthcare providers and warnings about serious harm or death if injected intravenously.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.